相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 克隆性:
多克隆
- 抗体英文名:
InVivoMAb anti-mouse Ly6G
- 抗体名:
小鼠体内用Ly6G抗体,体内Gr-1+骨髓细胞去除
- 规格:
5mg
InVivoMAb anti-mouse Ly6G
| 抗原 | 应用 | 克隆号 | InVivoMab 目录号 |
InVivoPlus 目录号 |
| PD-1 | 体内PD-1/PD-L1信号封闭 | RMP1-14 | BE0146 | BP0146 |
| 体内PD-1/PD-L1信号封闭,体外PD-1中和,IHC(冰冻),IF,WB,FC | 29F.1A12 | BE0273 | BP0273 | |
| 体内PD-1/PD-L1信号封闭,体外PD-1中和,WB | J43 | BE0033-2 | BP0033-2 | |
| InVivo rat IgG2a isotype control, PD-1同型对照,排除Fc段与抗原的非特异性结合 | 2A3 | BE0089 | BP0089 | |
| PD-L1(B7-H1) | 体内PD-L1信号封闭,IF,IHC(冰冻),FC,WB | 10F.9G2 | BE0101 | BP0101 |
| InVivo rat IgG2b isotype control, PD-L1同型对照,排除Fc段与抗原的非特异性结合 | LTF-2 | BE0090 | BP0090 | |
| CTLA-4 | 体内 CTLA-4 中和,WB | 9D9 | BE0164 | BP0164 |
| 体内和体外中和CTLA-4,WB | 9H10 | BE0131 | BP0131 | |
| 体内和体外中和CTLA-4,FC,WB | UC10- 4F10-11 |
BE0032 | BP0032 | |
| NK1.1 | 体内NK细胞去除,FC | PK136 | BE0036 | BP0036 |
| CD3ε | 体内T细胞去除,体外T细胞刺激/激活,IF,FC,WB, | 145-2C11 | BE0001-1 | BP0001-1 |
| CD4 | 体内CD4+T细胞去除,FC,WB | GK1.5 | BE0003-1 | BP0003-1 |
| CD8α | 体内CD8+T细胞去除,IF,FC,WB | 53-6.7 | BE0004-1 | BP0004-1 |
| CD25 (IL-2Rα) | 体内调节T细胞去除,FC | PC-61.5.3 | BE0012 | BP0012 |
| CD28 | 体内CD8封闭,体外T细胞刺激/激活 | 37.51 | BE0015-1 | / |
| 体外T细胞刺激/激活 | PV-1 | BE0015-5 | / | |
| CSF1R (CD115) | 体内巨噬细胞去除,体外CSF-R1中和,体内单核细胞去除, FC,WB | AFS98 | BE0213 | BP0213 |
| IL-4 | 体内IL-4中和,体外IL-4中和,体内IL-4受体刺激(as a complex with IL-4) FC,WB |
11B11 | BE0045 | BP0045 |
| IFNγ (interferon gamma) |
体内IFNγ中和,体外IFNγ中和,ELISPOT,FC,WB | XMG1.2 | BE0055 | BP0055 |
| Ly6G | 体内中性粒细胞耗竭,体内MDSC耗尽, IF,IHC(石蜡或冰冻),FC | 1A8 | BE0075-1 | BP0075-1 |
| Ly6G/Ly6C (Gr-1) | 体内Gr-1+骨髓细胞去除,IHC(石蜡或冰冻),FC | RB6-8C5 | BE0075 | BP0075 |
| IFNAR-1 | 体内IFNAR-1阻断,体外IFNAR-1阻断,WB | MAR1-5A3 | BE0241 | BP0241 |
| - | InVivoMab | InVivoPlus |
| 纯度 | >95% | >95% |
| 蛋白完整性 | √(SDS-PAGE) | √(SDS-PAGE) |
| 内毒素浓度 | <2EU/mg | <1EU/mg |
| 有效性验证(WB/FC/ELISA) | √ | |
| 蛋白聚集物<5% | √ | |
| 小鼠病原体测试 | √ | |
| 无叠氮化物和载体蛋白 | √ | √ |
| 大批量生产 | √ | √ |
| 适用体内研究 | √ | √ |
| 目录号 | 以BE开头 | 以BP开头 |
| 产品类型 | 品名 | 用途 | InVivoMab 目录号 |
InVivoPlus 目录号 |
| 部分热卖同型 对照 |
InVivoMab rat IgG2a isotype control | 排除一抗的Fc段与 抗原的非特异性结合, 使实验结果更加严谨, 有助于您发表高分论文 |
BE0089 | BP0089 |
| InVivoMab rat IgG2b isotype control | BE0090 | BP0090 | ||
| InVivoMab mouse IgG1 isotype control | BE0083 | BP0083 | ||
| InVivoMAb human IgG1 isotype control | BE0297 | BP0297 | ||
| InVivoPlus rat IgG2a isotype control | BE0089 | BP0089 | ||
| InVivoMab mouse IgG2a isotype control | BE0085 | BP0085 | ||
| InVivoMabrat IgG1 isotype control | BE0088 | BP0088 | ||
| InVivoPlus mouse IgG1 isotype control | BE0083 | BP0083 | ||
| InVivoMAb polyclonal Armenian hamster IgG | BE0091 | BP0091 | ||
| 抗体稀释Buffer | InVivoPure pH 7.0 Dilution Buffer | 官方指定抗体稀释 buffer,确保抗体使用 性能,加快您的实验进展 |
IP0070 | / |
| InVivoPure pH 6.5 Dilution Buffer | IP0065 | / |
About InVivoMAb anti-mouse Ly6G
The 1A8 monoclonal antibody reacts with mouse Ly6G. Ly6G is a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Ly6G is expressed differentially during development by cells in the myeloid lineage including monocytes, macrophages, granulocytes, and neutrophils. Monocytes typically express Ly6G transiently during development while mature granulocytes and peripheral neutrophils retain expression making Ly6G a good cell surface marker for these populations. Unlike the RB6-8C5 antibody, the 1A8 antibody reacts specifically with mouse Ly6G with no reported cross reactivity with Ly6C.InVivoMAb anti-mouse Ly6G Specifications
| Isotype | Rat IgG2a, κ |
| Recommended Isotype Control(s) | InVivoMAb rat IgG2a isotype control, anti-trinitrophenol(BE0089) |
| Recommended InVivoPure Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer(IP0070) |
| Immunogen | EL4J cells transfected with Ly6G |
| Reported Applications |
|
| Endotoxin |
|
| Purity |
|
| Formulation |
|
| Sterility | 0.2 μM filtered |
| Production | Purified from tissue culture supernatant in an animal free facility |
| Purification | Protein G |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| RRID | AB_1107721 |
| Molecular Weight | 150 kDa |
Application References
InVivoMAb anti-mouse Ly6G (Clone: 1A8)
Davis, R. W. t., et al. (2018). "Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy." Photochem Photobiol. PubMed Inflammatory cells, most especially neutrophils, can be a necessary component of the antitumor activity occurring after administration of photodynamic therapy. Generation of neutrophil responses has been suggested to be particularly important in instances when the delivered photodynamic therapy (PDT) dose is insufficient. In these cases, the release of neutrophil granules and engagement of antitumor immunity may play an important role in eliminating residual disease. Herein, we utilize in vivo imaging of luminol chemiluminescence to noninvasively monitor neutrophil activation after PDT administration. Studies were performed in the AB12 murine model of mesothelioma, treated with Photofrin-PDT. Luminol-generated chemiluminescence increased transiently 1 h after PDT, followed by a subsequent decrease at 4 h after PDT. The production of luminol signal was not associated with the influx of Ly6G(+) cells, but was related to oxidative burst, as an indicator of neutrophil function. Most importantly, greater levels of luminol chemiluminescence 1 h after PDT were prognostic of a complete response at 90 days after PDT. Taken together, this research supports an important role for early activity by Ly6G(+) cells in the generation of long-term PDT responses in mesothelioma, and it points to luminol chemiluminescence as a potentially useful approach for preclinical monitoring of neutrophil activation by PDT.风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验按摩的好处又添实锤!哈佛最新研究揭示:按摩真能修复受损肌肉,让你「痛并健康」着
时间内用按摩治疗小鼠中观察到的中性粒细胞清除。结果表明,与使用相应对照抗体治疗组相比,使用 Ly6g 抗体治疗的小鼠显示出显著减少的肌肉损伤和纤维化。对肌纤维大小的分析表明,肌肉按压治疗和中性粒细胞的缺失都使得肌肉纤维更长。此外,经抗 Ly6g 抗体去除中性粒细胞的受伤肌肉显示出更大的收缩力,其对功能恢复的影响与肌肉按压治疗的影响相似。上述这些发现表明,在这种损伤模型中,损伤肌肉中中性粒细胞丰度的时间控制与按压治疗对肌肉再生的影响相关。图片来源:Science Translational Medicine
与性别会影响到感染效率,一般会选择雄性小鼠做实验。 ② AAV2/3B 载体对人肝脏的感染效率明显,对 NHPS 也有效,但不能有效地转导 MOUSE 肝脏。 AAV 在肝脏应用中的局限及解决方式 肝细胞的自我更新会稀释体内 AAV 导致降低转导效率 重新注射新的血清型 使用药物阻断免疫应答重新注射同种血清型 AAV 基因整合到小鼠基因组上 体内预存的抗 AAV 中和抗体降低转导效率 实验前做中和抗体预筛,选择无中和抗体的小鼠 使用不同的血清型进行小鼠实验 预先处理小鼠来抑制其免疫应答再进行
内腔可产生高强度的磁场,足以分离磁微粒标记的细胞,无需分离柱提供提供更高强度的磁场。由于磁微粒极小,不会影响靶细胞的流式分析结果,因此不需要去除。除了现有的定型产品外,客户可选择EasySep® PE、FITC或生物素分选系统与自己的PE、FITC或生物素—偶联的单抗相结合,来富集任何所需的细胞。如果您有自己的小鼠IgG1抗任何细胞的抗体, 也可以使用“Do-It-Yourself”试剂盒做成TAC,用来分选您想要的细胞。此外,还可以根据您的特殊需要,专门为您设计定做试剂盒。用于正选小鼠的细胞
技术资料暂无技术资料 索取技术资料







